Gennova Biopharmaceuticals, a subsidiary of Pune-based Emcure Pharmaceuticals, is nearing completion of its phase II-III trials of their mRNA-based Covid-19 vaccine. Samit Mehta, president, Emcure, said they were expecting to complete trials in January 2022. The company has applied for manufacturing and stock piling of the vaccines at risk, Mehta said.

Gennova is the first Indian pharma company to develop an indigenous mRNA platform and the company has been working on this platform for the past four years.

Leave a Reply

Your email address will not be published. Required fields are marked *